J. W. Goldman

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Kwok‐Kin Wong, M. Koczywas, J. W. Goldman et al. · Journal of Clinical Oncology · 2011 · 62 citations

Cancer Epidemiology, Medicine, Hsp90 Inhibitor Ganetespib +14

A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

Adil Daud, Gregory M. Springett, David S. Mendelson et al. · Journal of Clinical Oncology · 2010 · 25 citations

Advanced Solid Tumors, Tumor Biology, Active Exposures +16

First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2.

Lee S. Rosen, David S. Mendelson, Richard B. Cohen et al. · Journal of Clinical Oncology · 2010 · 22 citations

Total Ang2, Immunology, Pharmacotherapy +21

First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort.

L. C. Chen, Lee S. Rosen, Tara Iyengar et al. · Journal of Clinical Oncology · 2011 · 14 citations

Final Results, Oncology, Cell Division +15

Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc)

Scott Gettinger, Naiyer A. Rizvi, Laura Q.M. Chow et al. · Annals of Oncology · 2014 · 13 citations

Platinum-based Doublet Chemotherapy, Medicine, Pharmacology +6